Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

v3.20.4
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Deficit [Member]
Balance, beginning at Dec. 31, 2017 $ 18,288 $ 37 $ 117,107 $ 41,276 $ (140,132)
Balance, beginning (in shares) at Dec. 31, 2017   36,634,856      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Cumulative effect adjustment on adoption | ASU 2016-01 [Member] 41,400     (41,361) 41,361
Beneficial conversion feature relating to convertible and promissory notes payable 13,374   13,374    
Exercise of stock options (in shares)   88,473      
Exercise of warrants 18,456 $ 1 18,455    
Exercise of warrants (in Shares)   1,741,720      
Common stock issued for cash (net of issuance cost) 1,275   1,275    
Common stock issued for cash (net of issuance cost) (in shares)   131,268      
Repurchase and cancellation of common stock (5,076) $ (1) (5,075)    
Repurchase and cancellation of common stock (in shares)   (1,254,924)      
Share-based compensation 4,546   4,546    
Foreign currency translation effect 16     16  
Net loss (72,587)       (72,587)
Balance, ending at Dec. 31, 2018 (21,708) $ 37 149,682 (69) (171,358)
Balance, ending (in shares) at Dec. 31, 2018   37,341,393      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Foreign currency translation effect 18        
Net loss (53,478)        
Balance, ending at Sep. 30, 2019 (12,249)        
Balance, beginning at Dec. 31, 2018 (21,708) $ 37 149,682 (69) (171,358)
Balance, beginning (in shares) at Dec. 31, 2018   37,341,393      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Cumulative effect adjustment on adoption | ASC 842 [Member] (29)       (29)
Beneficial conversion feature relating to convertible and promissory notes payable 8,765   8,765    
Common stock issued in merger (1,645) $ 2 (1,647)    
Common stock issued in merger ( in shares)   2,330,548      
Conversion of convertible notes payable and notes payable to common stock 39,499 $ 7 39,492    
Conversion of convertible notes payable and notes payable to common stock (in shares)   7,068,760      
Exercise of stock options 1   1    
Exercise of stock options (in shares)   175      
Exercise of warrants 186   186    
Exercise of warrants (in Shares)   53,557      
Common stock issued for cash (net of issuance cost) 8,589 $ 2 8,587    
Common stock issued for cash (net of issuance cost) (in shares)   1,677,013      
Warrant and conversion feature reclassified to equity 6,336   6,336    
Fair value of replacement equity awards 2,438   2,438    
Share-based compensation 1,367   1,367    
Foreign currency translation effect (10)     (10)  
Net loss (54,842)       (54,842)
Balance, ending at Dec. 31, 2019 $ (11,053) $ 48 $ 215,207 $ (79) $ (226,229)
Balance, ending (in shares) at Dec. 31, 2019   48,471,446